digestive intolerance and myelotoxicity) 6 are improved by lowering the dose of AZA, which is crucial to achieve adherence to treatment.Regarding severe medium-term risks (lymphomas, skin cancers), no data in IBD can be used to correlate 6-TGN levels and side effects.However, data in children with acute leukaemia or in patients with renal grafts and nonmelanoma skin cancer showed that elevated 6-TGN levels were an independent risk factor for these complications. 7,8 In any case, using a lower dose of a treatment resulting in the same efficacy than the full dose is unlikely to increase the risk of its side effects.
ACKNOWLEDGEMENTSThe authors' declarations of personal and financial interests are unchanged from those in the original article.